Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Sell
27
BBNX Quote, Financials, Valuation and Earnings
Last price:
$29.39
Seasonality move
:
--
Day range:
$28.76 - $30.93
52-week range:
$8.89 - $32.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
14.41x
P/B ratio:
4.39x
Volume:
929.1K
Avg. volume:
747.2K
1-year change:
--
Market cap:
$1.3B
Revenue:
$65.1M
EPS (TTM):
-$1.79
Analysts' Opinion
-
Consensus RatingBeta Bionics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $31.30, Beta Bionics, Inc. has an estimated upside of 6.54% from its current price of $29.38.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $23.00 representing 100% downside risk from its current price of $29.38.
Fair Value
-
According to the consensus of 9 analysts, Beta Bionics, Inc. has 6.54% upside to fair value with a price target of $31.30 per share.
BBNX vs. S&P 500
-
Over the past 5 trading days, Beta Bionics, Inc. has underperformed the S&P 500 by -6.55% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Beta Bionics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Beta Bionics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Beta Bionics, Inc. reported revenues of $27.3M.
Earnings Growth
-
Beta Bionics, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Beta Bionics, Inc. reported earnings per share of -$0.33.
Enterprise value:
1.1B
EV / Invested capital:
3.55x
Price / LTM sales:
14.41x
EV / EBIT:
--
EV / Revenue:
12.11x
PEG ratio (5yr expected):
-0.42x
EV / Free cash flow:
-17.72x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$48.3M
Return On Assets:
-31.27%
Net Income Margin (TTM):
-87.89%
Return On Equity:
-38.19%
Return On Invested Capital:
-36.9%
Operating Margin:
-62.54%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $53M | $88.6M | $16.7M | $27.3M | |
| Gross Profit | $1.2M | $29.3M | $48.3M | $8.9M | $15.1M | |
| Operating Income | -- | -$40.6M | -$68.6M | -$11M | -$17M | |
| EBITDA | -- | -$38.3M | -$66.1M | -$10.4M | -$16.4M | |
| Diluted EPS | -$0.20 | -$1.29 | -$1.79 | -$0.23 | -$0.33 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $82.6M | $270M | |
| Total Assets | -- | -- | -- | $96.9M | $330M | |
| Current Liabilities | -- | -- | -- | $17.9M | $25.4M | |
| Total Liabilities | -- | -- | -- | $64.1M | $35.3M | |
| Total Equity | -- | -- | -- | $32.9M | $294.8M | |
| Total Debt | -- | -- | -- | $5.9M | $5.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$40.3M | -$56.6M | -$9.6M | -$8.7M | |
| Cash From Investing | -- | -$43.4M | -$193.1M | $15.2M | $9.5M | |
| Cash From Financing | -- | -$1.3M | $270.7M | -$1.2M | $2.7M | |
| Free Cash Flow | -- | -$43.5M | -$60.5M | -$11.5M | -$10M | |
BBNX
Sector
Market Cap
$1.3B
--
Price % of 52-Week High
89.82%
--
Dividend Yield
0%
--
Shareholder Yield
-31.15%
--
1-Year Price Total Return
--
--
Beta (5-Year)
--
--
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$30.18
200-day SMA
Buy
Level
$18.26
Bollinger Bands (100)
Buy
Level
16.66 - 26.86
Chaikin Money Flow
Sell
Level
-3M
20-day SMA
Buy
Level
$28.94
Relative Strength Index (RSI14)
Buy
Level
55.55
ADX Line
Buy
Level
31.51
Williams %R
Neutral
Level
-51.3097
50-day SMA
Buy
Level
$25.12
MACD (12, 26)
Buy
Level
1.37
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
5.9M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Sell
CA Score
(Annual)
Level (-1.7551)
Sell
Beneish M-Score
(Annual)
Level (13.2295)
--
Momentum Score
Level (--)
Sell
Ohlson Score
Level (2.5339)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
Stock Forecast FAQ
In the current month, BBNX has received 8 Buy ratings 1 Hold ratings, and 0 Sell ratings. The BBNX average analyst price target in the past 3 months is $31.30.
-
Where Will Beta Bionics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Beta Bionics, Inc. share price will rise to $31.30 per share over the next 12 months.
-
What Do Analysts Say About Beta Bionics, Inc.?
Analysts are divided on their view about Beta Bionics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Beta Bionics, Inc. is a Sell and believe this share price will drop from its current level to $23.00.
-
What Is Beta Bionics, Inc.'s Price Target?
The price target for Beta Bionics, Inc. over the next 1-year time period is forecast to be $31.30 according to 9 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is BBNX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Beta Bionics, Inc. is a Buy. 8 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BBNX?
You can purchase shares of Beta Bionics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Beta Bionics, Inc. shares.
-
What Is The Beta Bionics, Inc. Share Price Today?
Beta Bionics, Inc. was last trading at $29.39 per share. This represents the most recent stock quote for Beta Bionics, Inc.. Yesterday, Beta Bionics, Inc. closed at $29.38 per share.
-
How To Buy Beta Bionics, Inc. Stock Online?
In order to purchase Beta Bionics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BBNX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BBNX
Sector
P/E ratio
--
--
PEG ratio
-0.42x
--
P/B ratio
4.39x
--
Price / LTM sales
14.41x
--
Growth Metrics
BBNX
Sector
Revenue growth
63.14%
--
Earnings growth
-43.31%
--
Revenue (5-year growth)
--
--
Earnings forecast
-$0.41
--
Profitability
BBNX
Sector
Profitability FY 2024
$35.9M
--
Return on invested capital
-36.9%
--
Return on assets
-31.27%
--
Return on equity
-38.19%
--
Earnings Date
Last Earnings Date
Oct
28
Next Earnings Date
Mar
24
Estimated Next Earnings Date
Jan
27
Balance Sheet
BBNX
Sector
Total cash
$228.7M
--
Short term investments
$73.1M
--
Total assets
$149.6M
--
Long term debt
$5.7M
--
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
